Alnylam Pharma (0HD2) Share Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0HD2 Analyst Ratings

Strong Buy

16 Buy

4 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Alnylam

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0HD2 Stock 12 Month Forecast

Average Price Target

$455.84

▲(38.01% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $455.84 with a high forecast of $580.00 and a low forecast of $351.00. The average price target represents a 38.01% change from the last price of $330.29.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"241":"$241","326":"$326","411":"$411","496":"$496","581":"$581"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":580,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$580.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":455.84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$455.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":351,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$351.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[241,326,411,496,581],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,339.41,357.9169230769231,376.42384615384617,394.9307692307693,413.4376923076923,431.9446153846154,450.45153846153846,468.95846153846156,487.46538461538466,505.9723076923077,524.4792307692308,542.9861538461539,561.493076923077,{"y":580,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,339.41,348.36615384615385,357.32230769230773,366.27846153846156,375.2346153846154,384.1907692307692,393.1469230769231,402.1030769230769,411.0592307692308,420.0153846153846,428.97153846153844,437.92769230769227,446.88384615384615,{"y":455.84,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,339.41,340.3015384615385,341.19307692307694,342.0846153846154,342.97615384615386,343.8676923076923,344.7592307692308,345.65076923076924,346.5423076923077,347.43384615384616,348.3253846153846,349.2169230769231,350.10846153846154,{"y":351,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":276.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.733,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":267.06,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":264.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.27,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":317.45,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":396.655,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":447.68,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":466.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.465,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.239,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":339.41,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$580.00

Average Price Target$455.84

Lowest Price Target$351.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$510

Buy

54.41%

Upside

Reiterated

02/18/26

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Moderna (NASDAQ: MRNA) and NewAmsterdam Pharma Company (NASDAQ: NAMS)

Whitney Ijem

Canaccord Genuity

$415→$429

Buy

29.89%

Upside

Reiterated

02/17/26

Canaccord Genuity Keeps Their Buy Rating on Alnylam Pharma (ALNY)

Eliana Merle

Barclays

$527

Buy

59.56%

Upside

Reiterated

02/17/26

Alnylam Pharma (ALNY) Receives a Buy from Barclays

Ritu Baral

TD Cowen

$482

Buy

45.93%

Upside

Reiterated

02/13/26

Alnylam Pharmaceuticals: Amvuttra-Driven Profitability Inflection Supports Long-Term Growth and Buy Rating

Cory Kasimov

Evercore ISI

$515→$400

Buy

21.11%

Upside

Reiterated

02/13/26

Evercore ISI Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

Danielle Brill

Truist Financial

$530→$515

Buy

55.92%

Upside

Reiterated

02/13/26

Truist Financial Remains a Buy on Alnylam Pharma (ALNY)

Keay Nakae

Chardan Capital

$425

Buy

28.67%

Upside

Reiterated

02/13/26

Chardan Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Michael Ulz

Morgan Stanley

$408→$360

Hold

9.00%

Upside

Reiterated

02/13/26

Morgan Stanley Sticks to Its Hold Rating for Alnylam Pharma (ALNY)

Kostas Biliouris

Oppenheimer

$500

Buy

51.38%

Upside

Reiterated

02/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Myles Minter

William Blair

―

Buy

―

Reiterated

02/12/26

Alnylam: Profitability Milestone and ATTR Momentum Underpin Durable Double-Digit Growth and Buy Rating

Joseph Stringer

Needham

$529→$510

Buy

54.41%

Upside

Reiterated

02/12/26

Alnylam: ATTR Franchise Momentum and Strategic Investment Support Durable Growth and Buy Rating

Paul Matteis

Stifel Nicolaus

$508→$444

Buy

34.43%

Upside

Reiterated

02/12/26

Alnylam price target lowered to $444 from $508 at StifelAlnylam price target lowered to $444 from $508 at Stifel

William Pickering

Bernstein

$491→$451

Buy

36.55%

Upside

Assigned

02/12/26

Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Sysmex (SSMXF)

Olivia Brayer

Cantor Fitzgerald

$400

Hold

21.11%

Upside

Reiterated

02/12/26

Cantor Fitzgerald Sticks to Their Hold Rating for Alnylam Pharma (ALNY)

Luca Issi

RBC Capital

$465→$450

Buy

36.24%

Upside

Reiterated

02/12/26

RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$510

Buy

54.41%

Upside

Reiterated

02/18/26

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Moderna (NASDAQ: MRNA) and NewAmsterdam Pharma Company (NASDAQ: NAMS)

Whitney Ijem

Canaccord Genuity

$415→$429

Buy

29.89%

Upside

Reiterated

02/17/26

Canaccord Genuity Keeps Their Buy Rating on Alnylam Pharma (ALNY)

Eliana Merle

Barclays

$527

Buy

59.56%

Upside

Reiterated

02/17/26

Alnylam Pharma (ALNY) Receives a Buy from Barclays

Ritu Baral

TD Cowen

$482

Buy

45.93%

Upside

Reiterated

02/13/26

Alnylam Pharmaceuticals: Amvuttra-Driven Profitability Inflection Supports Long-Term Growth and Buy Rating

Cory Kasimov

Evercore ISI

$515→$400

Buy

21.11%

Upside

Reiterated

02/13/26

Evercore ISI Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

Danielle Brill

Truist Financial

$530→$515

Buy

55.92%

Upside

Reiterated

02/13/26

Truist Financial Remains a Buy on Alnylam Pharma (ALNY)

Keay Nakae

Chardan Capital

$425

Buy

28.67%

Upside

Reiterated

02/13/26

Chardan Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Michael Ulz

Morgan Stanley

$408→$360

Hold

9.00%

Upside

Reiterated

02/13/26

Morgan Stanley Sticks to Its Hold Rating for Alnylam Pharma (ALNY)

Kostas Biliouris

Oppenheimer

$500

Buy

51.38%

Upside

Reiterated

02/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Myles Minter

William Blair

―

Buy

―

Reiterated

02/12/26

Alnylam: Profitability Milestone and ATTR Momentum Underpin Durable Double-Digit Growth and Buy Rating

Joseph Stringer

Needham

$529→$510

Buy

54.41%

Upside

Reiterated

02/12/26

Alnylam: ATTR Franchise Momentum and Strategic Investment Support Durable Growth and Buy Rating

Paul Matteis

Stifel Nicolaus

$508→$444

Buy

34.43%

Upside

Reiterated

02/12/26

Alnylam price target lowered to $444 from $508 at StifelAlnylam price target lowered to $444 from $508 at Stifel

William Pickering

Bernstein

$491→$451

Buy

36.55%

Upside

Assigned

02/12/26

Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Sysmex (SSMXF)

Olivia Brayer

Cantor Fitzgerald

$400

Hold

21.11%

Upside

Reiterated

02/12/26

Cantor Fitzgerald Sticks to Their Hold Rating for Alnylam Pharma (ALNY)

Luca Issi

RBC Capital

$465→$450

Buy

36.24%

Upside

Reiterated

02/12/26

RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

3 Months

xxx

Success Rate

20/31 ratings generated profit

Average Return

+7.88%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.52% of your transactions generating a profit, with an average return of +7.88% per trade.

1 Year

Kostas BiliourisOppenheimer

Success Rate

20/23 ratings generated profit

Average Return

+40.30%

a rating ―

Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +40.30% per trade.

2 Years

xxx

Success Rate

22/23 ratings generated profit

Average Return

+93.67%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.65% of your transactions generating a profit, with an average return of +93.67% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HD2 Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0HD2 has received 38 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. 0HD2 average Analyst price target in the past 3 months is 455.84.

Each month's total comprises the sum of three months' worth of ratings.

0HD2 Financial Forecast

0HD2 Earnings Forecast

Next quarter’s earnings estimate for 0HD2 is $0.99 with a range of $0.04 to $1.65. The previous quarter’s EPS was $0.82. 0HD2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.

0HD2 Sales Forecast

Next quarter’s sales forecast for 0HD2 is $1.15B with a range of $1.02B to $1.46B. The previous quarter’s sales results were $1.10B. 0HD2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.

0HD2 Stock Forecast FAQ

What is GB:0HD2’s average 12-month price target, according to analysts?

Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 455.84.

What is GB:0HD2’s upside potential, based on the analysts’ average price target?

Alnylam Pharmaceuticals has 38.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Alnylam Pharmaceuticals a Buy, Sell or Hold?

Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 16 buy ratings, 4 hold ratings and 0 sell ratings.

What is Alnylam Pharmaceuticals’s share price target?

The average share price target for Alnylam Pharmaceuticals is 455.84. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $580.00 ,and the lowest forecast is $351.00. The average share price target represents 38.01% Increase from the current price of $330.29.

What do analysts say about Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Alnylam Pharmaceuticals?

To buy shares of GB:0HD2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Alnylam Pharma (0HD2) Share Forecast & Price Target

0HD2 Analyst Ratings

0HD2 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alnylam Pharma

0HD2 Analyst Recommendation Trends

0HD2 Financial Forecast

0HD2 Earnings Forecast

0HD2 Sales Forecast

0HD2 Stock Forecast FAQ

Detailed List of Analyst Forecasts